Potential surrogate endpoints in cancer research - Some considerations and examples

Pharmaceutical Statistics

Volumn 10, Issue 1, 2011, Pages 34-39

  Duffy, S W ^a   Treasure, F P ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

biomarkers; cancer; clinical trials; surrogacy; surrogate endpoints

Indexed keywords

BIOLOGICAL MARKER; CA 15-3 ANTIGEN; PROSTATE SPECIFIC ANTIGEN; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; CANCER RESEARCH; CANCER SURVIVAL; EPSTEIN BARR VIRUS; HEALTH SURVEY; HUMAN; NASOPHARYNX CANCER; OUTCOME ASSESSMENT; PROSTATE CANCER; PROSTATECTOMY; SENSITIVITY AND SPECIFICITY; VALIDITY;

BIOLOGICAL MARKERS; BIOMARKERS, PHARMACOLOGICAL; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; VALIDATION STUDIES AS TOPIC;

EID: 79551561870     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.406     Document Type: Article

References (47)

1. Senn S., Statistical Issues in Drug Development (2nd edn). Wiley: Chichester, 2008.
2. Cuzick J, Cafferty FH, Edwards R, MÃ?ller H, Duffy SW,. Surrogate endpoints for cancer screening trials: general principles and an illustration using the UK Flexible Sigmoidoscopy Screening Trial. Journal of Medical Screening 2007; 14: 178-185.
3. Biomarker Definition Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clinical Pharmacology and Therapeutics 2001; 69: 89-95.
4. Bloom JC, Dean RA,. Biomarkers in Clinical Drug Development. Marcel Dekker: New York, 2003.
5. Day NE, Duffy SW,. Trial design based on surrogate end points-application to comparison of different breast screening frequencies. Journal of the Royal Statistical Society (A) 1996; 159: 49-60.
6. Hilsenbeck SG, Clark GM,. Surrogate endpoints in chemoprevention of breast cancer: guidelines for evaluation of new biomarkers. Journal of Cellular Biochemistry-Supplement 1993; 17G: 205-211.
7. Byrne GJ, Bundred NJ,. Surrogate markers of tumour angiogenesis. International Journal of Biological Markers 2000; 15: 334-339.
8. Tangen CM, Crowley JJ,. Phase II trials using time-to-event endpoints. In Handbook of Statistics in Clinical Oncology (2nd edn), Crowley J, Ankerst DP, (eds). Chapman & Hall, CRC: Boca Raton, 2006.
9. Green S, Benedetti J, Crowley J., Clinical Trials in Oncology (2nd edn). Chapman & Hall, CRC: Boca Raton, 2003.
10. Rustin GJS, Bast RC, Kelloff GJ, Barrett JC, Carter SK, Nisen PD, Sigman CC, Parkinson DR, Ruddon RW,. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clinical Cancer Research 2004; 10: 3919-3926.
11. Burzykowski T, Molenberghs G, Buyse M., The Evaluation of Surrogate Endpoints. Springer: Heidelberg, 2005.
12. Prentice RL,. Surrogate endpoints in clinical trials: definitions and operational criteria. Statistics in Medicine 1989; 8: 431-440.
13. Begg CB, Leung DHY,. On the use of surrogate end points in randomized trials. Journal of the Royal Statistical Society A 2000; 163: 15-24.
14. Baker SG, Kramer BS,. A perfect correlate does not a surrogate make. BMC Medical Research Methodology 2003; 3: 16.
15. Buyse M, Molenberghs G,. The validation of surrogate endpoints in randomized experiments. Biometrics 1998; 54: 1014-1029.
16. Freedman LS, Graubard BI, Schatzkin A,. Statistical validation of intermediate endpoints for chronic diseases. Statistics in Medicine 1992; 11: 167-178.
17. Tabar L, Fagerberg G, Chen HH, Duffy SW, Smart CR, Gad A, Smith RA,. Efficacy of breast cancer screening by age: new results from the Swedish two-county trial. Cancer 1995; 75: 2507-2517.
18. Duffy SW, Tabar L, Fagerberg G, Gad A, Grontoft O, South MC, Day NE,. Breast screening, prognostic factors and survival-results from the Swedish two-county study. British Journal of Cancer 1991; 64: 1133-1138.
19. Flandre P, Saidi Y,. Estimating the proportion of treatment effect explained by a surrogate marker. Statistics in Medicine 1999; 18: 107-109.
20. Molenberghs G, Buyse M, Geys H, Renard D, Burzykowski T, Alonso A,. Statistical challenges in the evaluation of surrogate endpoints in randomized trials. Controlled Clinical Trials 2002; 23: 607-625. (Pubitemid 36005472)
21. Alonso A, Molenberghs G, Burzykowski T, Renard D, Geys H, Shkedy Z, Tibaldi F, Abrahantes JC, Buyse M,. Prentice's approach and the meta-analytic paradigm: a reflection on the role of statistics in the evaluation of surrogate endpoints. Biometrics 2004; 60: 724-728.
22. Qu Y, Case M,. Quantifying the effect of the surrogate marker by information gain. Biometrics 2007; 63: 958-960.
23. Alonso A, Molenberghs G,. Surrogate marker evaluation from an information theory perspective. Biometrics 2007; 63: 180-186.
24. Cheng W-M, Chan KH, Chen H-L, Luo R-X, Ng SP, Luk W, Zheng B-J, Ji M-F, Liang J-S, Sham JST, Wang DK, Zong Y-S, Ng MH,. Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum. International Journal of Cancer 2002; 97: 489-492.
25. Chen HH, Prevost TC, Duffy SW,. Evaluation of screening for nasopharyngeal carcinoma: trial design using Markov chain models. British Journal of Cancer 1999; 79: 1894-1900.
26. Chan ATC, Teo PML, Johnson PJ,. Nasopharyngeal carcinoma. Annals of Oncology 2002; 13: 1007-1015.
27. Barqawi AB, Moul JW, Ziada A, Handel L, Crawford ED,. Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy. Urology 2003; 62: 872-876.
28. Moul JW,. Variables in predicting survival based on treating 'PSA-only' relapse. Urologic Oncology 2003; 21: 292-304.
29. D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen M-H,. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. Journal of the National Cancer Institute 2003; 95: 1376-1383.
30. Albertsen PC, Hanley JA, Penson DF, Fine J,. Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation. Journal of Urology 2004; 171: 2221-2225.
31. Collette L, Burzykowski T, Carroll KJ, Newling D, Morris T, Schröder FH,. Is prostate-specific antigen a valid surrogate endpoint for survival in hormonally treated patients with metastatic prostate cancer? Journal of Clinical Oncology 2005; 23: 6139-6148.
32. Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MHA, Lara PM, Jones JA, Taplin ME, Burch PA, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED,. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. Journal of the National Cancer Institute 2006; 98: 516-552.
33. [, Baker SG, (editorial): Journal of the National Cancer Institute 2006; 502-503 ].
34. Armstrong AJ, Garrett-Mayer E, Ou Yang YC, Carducci MA, Tannock I, de Wit R, Eisenberger M,. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. Journal of Clinical Oncology 2007; 25: 3965-3970.
35. Collette L, Buyse M, Burzykowski T,. Are prostate-specific antigen changes valid surrogates for survival in hormone-refractory cancer? A meta-analysis is needed! Journal of Clinical Oncology 2007; 25: 5673-5674.
36. Barrenetxea G, Schneider J, Centeno MM, Genollá J, Lorente F, Rodríguez-Escudero FJ,. CA15.3: A breast cancer marker predicting location of metastases even before treatment. European Journal of Cancer 1996; 32 (Supp. 1): S17.
37. Cuzick J, Forbes J, Edwards R, et al,. First results from the international breast cancer intervention study (IBIS): a randomized prevention trial. Lancet 2002; 360: 817-824.
38. Cuzick J, Warwick J, Pinney E, Warren RML, Duffy SW,. Effect of tamoxifen on women at increased risk of breast cancer. Journal of the National Cancer Institute 2004; 96: 621-628.
39. Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M, Labianca R, Seitz JF, O'Callaghan CJ, Francini G, Grothey A, Connell M, Catalano PJ, Blanke CD, Kerr D, Green E, Wolmark N, Andre T, Goldberg RM, De Gramont A,. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20 898 patients on 18 randomized trials. Journal of Clinical Oncology 2005; 23: 8664-8670.
40. Gill S, Sargent D,. End points for adjuvant therapy trials: has the time come to accept disease-free survival as a surrogate end point for overall survival? The Oncologist 2006; 11; 624-629.
41. Buyse M, Burzykowski T, Carroll K, Michiels S, Sargent DJ, Miller LL, Elfring GL, Pignon JP, Piedbois P,. Progression-free survival is a surrogate for survival in advanced colorectal cancer. Journal of Clinical Oncology 2007; 25: 5218-5224. (Pubitemid 350232253)
42. Burzykowski T, Buyse M, Piccart-Gebhart MJ, Sledge G, Carmichael J, Lück H-J, Mackey JR, Nabholtz J-M, Paridaens R, Biganzoli L, Jassem J, Bontenbal M, Bonneterre J, Chan S, Basaran GA, Therasse P,. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. Journal of Clinical Oncology 2008; 26: 1987-1992.
43. Sargent DJ, Hayes DF,. Assessing the measure of a new drug: is survival the only thing that matters? Journal of Clinical Oncology 2008; 26: 1922-1923.
44. Temple R,. Are surrogate markers adequate to assess cardiovascular disease drugs? Journal of the American Medical Association 1995; 282: 790-795.
45. Weir CJ, Walley RJ,. Statistical evaluation of biomarkers as surrogate endpoints: a literature review. Statistics in Medicine 2006; 25: 183-203.
46. Alonso A, Molenberghs G, Geys H, Buyse M, Vangeneugden T,. A unifying approach for surrogate marker validation based on Prentice's criteria. Statistics in Medicine 2006; 25: 205-221.
47. Qu Y, Case M,. Quantifying the indirect treatment effect via surrogate markers. Statistics in Medicine 2006; 25: 223-231.